Catalyst Pharmaceuticals (CPRX) Downgraded by BidaskClub

BidaskClub cut shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) from a buy rating to a hold rating in a report published on Saturday.

CPRX has been the subject of a number of other research reports. Zacks Investment Research downgraded Catalyst Pharmaceuticals from a hold rating to a sell rating in a research report on Wednesday, October 11th. HC Wainwright restated a buy rating and set a $6.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Friday, November 10th. Roth Capital set a $5.00 price objective on Catalyst Pharmaceuticals and gave the stock a buy rating in a research note on Wednesday, November 1st. Piper Jaffray Companies set a $8.00 price objective on Catalyst Pharmaceuticals and gave the stock a buy rating in a research note on Friday, December 1st. Finally, SunTrust Banks set a $5.00 price objective on Catalyst Pharmaceuticals and gave the stock a buy rating in a research note on Tuesday, October 31st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. The company presently has an average rating of Buy and a consensus price target of $6.25.

Catalyst Pharmaceuticals (CPRX) traded down $0.07 during mid-day trading on Friday, reaching $3.88. The company’s stock had a trading volume of 605,800 shares, compared to its average volume of 597,880. Catalyst Pharmaceuticals has a 1 year low of $1.03 and a 1 year high of $4.51. The stock has a market capitalization of $333.86, a P/E ratio of -18.48 and a beta of 1.68.

Several institutional investors and hedge funds have recently modified their holdings of CPRX. Schwab Charles Investment Management Inc. acquired a new position in shares of Catalyst Pharmaceuticals during the second quarter worth about $333,000. Rhumbline Advisers acquired a new position in shares of Catalyst Pharmaceuticals during the second quarter worth about $209,000. State of Wisconsin Investment Board acquired a new position in shares of Catalyst Pharmaceuticals during the second quarter worth about $149,000. Bank of New York Mellon Corp lifted its stake in shares of Catalyst Pharmaceuticals by 206.4% during the second quarter. Bank of New York Mellon Corp now owns 211,979 shares of the biopharmaceutical company’s stock worth $585,000 after purchasing an additional 142,803 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in shares of Catalyst Pharmaceuticals by 1,833.2% during the second quarter. JPMorgan Chase & Co. now owns 1,536,300 shares of the biopharmaceutical company’s stock worth $4,240,000 after purchasing an additional 1,456,830 shares in the last quarter. Institutional investors own 34.75% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this news story on another domain, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this news story can be viewed at https://www.com-unik.info/2018/01/09/catalyst-pharmaceuticals-cprx-downgraded-by-bidaskclub.html.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.

What are top analysts saying about Catalyst Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Catalyst Pharmaceuticals and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit